December 23, 2009
| Bio-IT World

Industry Trends
Loading...

Pharma/Biotech
In-licensing Trends,
2005 -- 2008

By Mark P. Mathieu
Biotechnology in-licensing activity with large pharmaceutical manufacturers witnessed a dramatic acceleration beginning in 2006.   Estimates revealed total up-front considerations paid to biotech companies accelerated 42% to $1.6bn in 2006, up from $1.1bn in 2005; increased 32% to $2.6bn in 2008.  Read More


Top Headlines


Pharma's Love Affairs
|

The Motley Fool | If 2007 was the year pharma fell in love with biologics, then 2009 was the year it finally learned to love itself.

more
Aveo Pharmaceuticals Files for IPO
|

Bio-IT World | Aveo Pharmaceuticals, a former Bio-IT World "company to watch," signaled a brighter 2010 for the pharma industry by filing for an Initial Public Offering.

more
Lung Cancer and Melanoma Mapped
|

ABC News | Scientists at the Wellcome Trust Sanger Institute have mapped lung and skin cancer in what is being called a breakthrough that could revolutionize cancer care. The two studies were published today in Nature.

more

MORE NEWS BELOW

Get Adobe Flash player


Leprosy Susceptibility Genes Identified
|

Bio-IT World | Scientists at the Genome Institute of Singapore (GIS) have completed the first-ever genome-wide association study of leprosy and the largest GWAS effort on infectious disease. In collaboration with 26 institutes in China, GIS identified seven genes that cause people to be susceptible to leprosy. The results were published yesterday in the New England Journal of Medicine.

more
Cancer Genomes Suggest One Mutation Every 15 Cigarettes
|

The Times | Scientists from the Wellcome Trust Sanger Institute and Life Technologies have reconstructed the biological history of two types of cancer in a genetic tour de force that promises to transform medical treatment of the disease.

more
George Church's Challenge to the Genomics Generation
|

Newsweek | George Church talks about the history of personal genomics, the benefits of genome mapping, and the responsibiliteis of the first genomic generation.

more

White Papers & Special Reports

Thomson Reuters Biomarkers wp
The Promise of Imaging Biomarkers
Sponsored by Thomson Reuters

Imaging biomarkers are poised to join biochemical and molecular markers as drivers of drug development and disease management. They enable researchers and clinicians to see into the body without invasive procedures. They frequently provide earlier detection of disease and its progression than molecular markers. Researchers use them to see in detail how their candidate drugs behave such as determining the percentage of target receptors occupied by a drug or observing a drug's ability to cross the blood/brain barrier. They promise to save time and money too.
Download this white paper in which experts analyze imaging biomarkers’ great promise and explore:

  • Important trends in R&D and disease management
  • Key technical and commercialization challenges
  • Promising avenues for progress in the field- with examples of successful use of imaging biomarkers.
Adobe Beyond EDC whitepaper
Beyond EDC…Optimizing ROI by Streamlining Clinical Research Processes
Sponsored by Adobe

Although EDC brings tremendous efficiencies to clinical data collection, numerous repetitive clinical development activities exist beyond its scope which are in need of more efficient processes.  As these activities move from paper-based to electronic, the transition can be eased through the use of intelligent PDF forms.  Using XML capabilities, intelligent forms can follow workflows while leveraging established point solutions such as EDC, CTMS and IV/IWRS to optimize return on investment.
This White Paper describes:

  • How intelligent PDF forms can accelerate repetitive clinical development processes, leading to faster development timelines
  • How return on investment is maximized by being able to repeat time and cost savings across nearly all development phases and therapeutic areas
SURETY-IP_WPx108
Protect Your Scientific Intellectual Property: Proof of Lab Informatics Data Authenticity is Your Best Legal Defense
Sponsored by Surety, LLC

As a bio-technology or life sciences organization, your formulas, treatments and research and discoveries are the “lifeblood” of your business. But if you aren't protecting the integrity of your scientific data in your lab informatics systems, you risk losing IP ownership, revenue and consequently your business if you can't prove time-of-creation and data authenticity. Learn how you can implement simple, cost-effective and automated controls to protect your scientific intellectual property. Consider:

  • IP protection requirements in bio-pharma and other science-oriented industries can extend out 20, 30, 40 or more years
  • Most electronic lab management solutions include generic authenticity controls, so how "legally defensible" is yours?
  • Only standards-compliant, independent controls can future-proof your approach to long-term IP integrity protection and authenticity.
  • Learn more - get the free whitepaper now


Expert Comment

Loading...

Performing in the Downturn and Beyond

By Jean-Marc Neimetz
Capgemini Consulting

November 10, 2009 | The life sciences industry is in a catch-22 situation accentuated by the current economic crisis, according to the eighth edition of Capgemini Consulting’s Vision & Reality report, Life Sciences: Performing in the Downturn and Beyond. Comprised of in-depth interviews with industry executives representing pharmaceutical, biotech, medical device, and agrichemical companies in Europe and North America, the report presents a perspective on cost initiatives affecting all life science industry players.

Innovation costs are escalating. Outcome-based trials and regulatory requirements are more complex, raising costs for new product approval and release. Meanwhile, price pressures, the combination of generics and shortened market exclusivity limit pharmaceuticals’ ability to fund innovation. Read more.

Bio-IT World invites contributed Expert Commentaries. Contact Kevin Davies with proposals.

Life Science Webcasts & Podcasts

Technology Challenges and Outlook for Drug Safety Management in Clinical Trials 
Sponsored by Medidatamedidata

This podcast will discuss the drug safety regulation challenges that the biopharmaceutical industry is facing in clinical trials and the emerging new technologies that can help researchers to address them.
 
Industry experts and executives from Medidata will address the following questions:

  • What are the challenges associated with drug safety in clinical trials?
  • How can a clinical study sponsor be better prepared for regulatory agency safety inspections?
  • What is the outlook of technology in safety data management?

Download now


Related Web Sites

Loading...
 eCliniqua

Innovative management in clinical trials

 Barnett Educational Services

Leaders in quality training resources

 Insight Pharma Reports

Reports evaluating issues in pharmaceutical technology, business, and therapeutic markets


Bio-IT Briefs

| Bio-IT World | FULL STORIES


Job Openings

Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.